EXOSOME-BASED LIQUID BIOPSY
Craif is a pioneer in exosome-based liquid biopsy for accurate and unpainful early cancer detection.
We aim to create a society where everyone can stay healthy throughout their lifetime.
Craif CTO, Dr. Ichikawa, made a presentation at the 81st Discussion Session of the Japan Society for Analytical Chemistry.
Craif present results of urine-based urothelial cancer detection at the American Association of Cancer Research (AACR) Annual Meeting 2021
Craif Inc. Announces Residency at JLABS @ Shanghai To Further Accelerate the Development of an Innovative Exosome Biomarker Discovery Platform
Forbes has announced that CEO Ryuichi Onose has been selected for the “Forbes 30 Under 30 Asia 2021” in the Healthcare & Science category
Enrichment of exosomes from body fluid efficiently with a simple procedure allows a more accurate interpretation of cellular communications